We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

DEST Destiny Pharma Plc

2.00 (2.72%)
08 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Destiny Pharma Plc LSE:DEST London Ordinary Share GB00BDHSP575 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  2.00 2.72% 75.50 175,376 13:26:49
Bid Price Offer Price High Price Low Price Open Price
74.00 77.00 75.50 73.00 73.50
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations -6.5M -0.0683 -11.05 71.93M
Last Trade Time Trade Type Trade Size Trade Price Currency
17:06:47 O 9,577 75.77 GBX

Destiny Pharma (DEST) Latest News

Destiny Pharma (DEST) Discussions and Chat

Destiny Pharma Forums and Chat

Date Time Title Posts
08/12/202315:29Destiny Pharma plc2,257
22/11/202212:29Destiny Pharma1

Add a New Thread

Destiny Pharma (DEST) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-12-08 17:17:4175.779,5777,256.49O
2023-12-08 17:06:4775.505,0003,775.00O
2023-12-08 16:31:5574.5025,00018,625.00O
2023-12-08 16:27:0875.883,2232,445.61O
2023-12-08 16:22:5875.883,9452,993.47O

Destiny Pharma (DEST) Top Chat Posts

Top Posts
Posted at 16/11/2023 09:02 by captain james t kirk
And the analysts also said this:

"Valuation: no change to 285p target price We reiterate our target price for Destiny Pharma of 285p. We note that the signing of a licensing agreement would help further de-risk Destiny’s equity story and is likely to result in a material uplift of the share price. Upon the potential announcement of a strategic partnership and disclosure of any licensing deal terms we will look to revise our current valuation assumptions."
Posted at 30/10/2023 09:50 by xxproinvestorxx
This month Bill turned 61 so I would presume retirement is something on his mind. Dest is his only appointment as a director, so it is logical to assume his 6.5M shares constitutes a large proportion of his net wealth. The only way for him to extract any value, would be to sell his shares. However, doing so on the open market would be devastating to the share price.

Of course, he could be waiting for further value inflection points and the completion of Phase 3 trials for M3 and/or XF-73, however it will be several years before Dest reach commercialisation should P3 trials be successful. Additional funding is also likely to be required (depending upon XF-73 deal terms) and, currently, it is probable that this would come from share placements, albeit at considerably higher market cap and share price than present.

Of course this is all speculation on my part, but I'd like to know others thoughts?
Posted at 30/10/2023 09:21 by xxproinvestorxx
I'm surprised at the slip back in share price last week but then this is the Aim market.

One thing I find curious is that both Chris and Bill have transferred a large proportion of their shares to their spouses in the past month. Bills are particularly intriguing, with 2.3M shares transferred on the 4th Oct. Chis has only just joined the company so there is less weight behind his transfer as he transferred the share shortly after purchasing them.

But this still raised the question - why have they both transferred such a large number of shares? And why now? The shares were not transferred (by Bill) prior to the M3 deal, or had much interaction with the share in the past two years. The only logical conclusion I can deduce is that it optimises and reduces their taxes. However, this would only be a consideration if they are a. expecting a significant uplift in the share price and b. expecting to exit soon.

We know they are searching for a partner for XF-73, but could a full acquisition be on the cards? And if so what price would someone have to pay?

The current climate is pretty dire for raising capital, and there has been a drop-off in pharma deals recently, but many large pharma companies are sitting on large cash stock-piles. In addition, Dest have a significant advantage and are de-risked compared with other small pharma companies listed on Aim - with M3 & XF-73 both Phase 3 ready, a partner and deal worth up to $570M + royalties for the former, and, cash runway into 2025.
Posted at 17/10/2023 09:20 by z1co
Destiny Pharma to share new data, discuss commercial potential of gel with analysts and investors

Published: 07:28 17 Oct 2023

Clinical-stage biotechnology company Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) said it will present new microbiological data on one of its lead assets, XF-73, as well as discussing its commercial potential at a meeting of analysts and investors later on Tuesday (17 October).

A new study published in the Frontiers in Cellular and Infection Microbiology scientific journal tested how well XF-73 works against a type of bacteria called Staphylococcus, or Staph for short.

The evaluation looked at over 2,500 samples of this bacteria from 33 different countries and 16 different kinds.

The phase III-ready preventative was effective against all breeds tested, even the ones that are usually resistant to antibiotics.

It worked against the particularly tough-to-kill MRSA strain, which is known to cause severe infections. The gel was worked against six other important types of Staph bacteria as well.

The latest data will be the centrepiece of a meeting in the City scheduled for today at 14:00 BST/09:00 EDT, which will include presentations from leading experts in the field of microbiology and healthcare.

Consultant microbiologist professor Mark Wilcox, who serves as the head of research and development in microbiology at Leeds Teaching Hospital, and Richard Proctor, professor emeritus of medicine and medical microbiology and immunology at the University of Wisconsin-Madison, will address the issue of surgical site infections and their impact on healthcare systems.

Real-world scenarios from the wards will be presented by Dr Alex Mericli, associate professor and plastic surgeon at MD Anderson Cancer Center, and Mr Raghbir Khakha, consultant trauma and orthopaedic surgeon at Guy's and St Thomas's Hospital.

An interview with a UK patient who contracted a Staphylococcus aureus infection following surgery for a torn anterior cruciate ligament will also feature in the meeting.

"The potential of XF-73 nasal is one of the reasons I was motivated to join Destiny Pharma in its mission to reduce the emergence and impact of drug-resistant pathogens with preventative solutions," said Destiny CEO Chris Tovey.

"The innovative XF platform includes a blockbuster, $2bn plus opportunity in the US alone, but has also shown utility beyond surgical site infections to address fungal and dermal infections as well.

"Most importantly, it has the potential to play an essential role in protecting vulnerable patients, and in doing so, save lives."
Posted at 20/9/2023 11:18 by sev22
Introduction to a research note published by Cavendish Capital Markets Ltd, Destiny's joint broker.

Late-stage assets continue to be in focus.

Destiny Pharma’s H1 2023 interim results provided an overview of what has been a busy period of positive activity for the company. The group strengthened its balance sheet through the completion of an equity fundraise, generating £7.3m in gross proceeds, ending the period with a net cash position of £9.8m. Management has guided that the current cash reserves provide an operating cash runway into Q1 2025. In our view, given the currently turbulent biotech financing environment, the successful raise reflects the positive investor sentiment that underpins the value of Destiny’s R&D pipeline. Operationally, the key highlight for the period was the $570m North American licensing deal with Sebela Pharmaceuticals to progress clinical development of NTDM3 into Phase III studies and towards commercialisation. The deal not only aids in de-risking Destiny’s equity story but supports management’s ability to execute and capitalise on licensing opportunities that can create value for shareholders.

Upcoming news flow and catalysts.

Whilst it is difficult to accurately predict timing, in our view, the signing of a licensing agreement for XF-73 represents the next major catalyst for Destiny. Management, in consultation with specialist consultants, undertook an independent market analysis during H1 2023 with clinicians and payers in the US and EU confirming XF-73’s superior treatment profile against current standard of care. This further supports the potential $2bn market opportunity for XF-73 in the US alone (previously >$1bn) and, together with the encouraging clinical data package, should help command favourable terms with potential licensing suitors, in our view. We expect to see news flow corresponding to XF-73’s progress within the next 12 months.

We maintain our target price of 285p.
Posted at 31/7/2023 19:07 by mrk74
Bones698,agreed Phase 3 trial data will be sometime in coming but there are many more milestones/share price drivers for Dest between now and then. As you know, the real catalyst to drive the share price over the next 3-9months is a partnership on XF-73 nasal (NB the report published today references XF-73 dermal - an earlier stage/ different workstream/programme and a whole different opportunity set). The collabaration you refer to with not much money upfront is for the development of NTCD-M3 where Sebela have agreed to fully fund the development to commercialisation of the product in return for US rights (RoW partnerships still in play). Sebela paid Dest $1m upfront, have agreed to pay another $19m in development milestone payments and sales revenue payments up to $550m (plus royalties on top). Agreed, the upfront payment could be argued to be disappointing but the cost to Sebela to fully fund the development needs to be included in the equation too. Irrespective, I dont think any investor/anyone with knowledge of Destiny would argue that the real value is more likely to be in the XF-73 platform and in particular in the XF-73 nasal partnership agreement as and when it comes.
Posted at 02/5/2023 15:28 by eva_1989
Sold half of my holding with breakeven

keeping £50K worth now

Sell 14,711 @ GBP0.3413 Destiny Pharma Plc
£5,000.13 £236,491.51
Sell 14,711 @ GBP0.3413 Destiny Pharma Plc
£5,000.13 £231,491.38
Sell 29,455 @ GBP0.3401 Destiny Pharma Plc
£9,998.03 £226,491.25
Sell 49,660 @ GBP0.3428 Destiny Pharma Plc
£17,000.01 £216,493.22
Sell 40,932 @ GBP0.3426 Destiny Pharma Plc
£14,000.26 £199,493.21

I'm just not happy with few things i mentioned earlier and wanted to trimmed down position rather than add here

i will buy if i show management also buying else happy to wait with whatever holding I've

with my less holding, i will cry less here.

But what a mess this management has made to this share

2 P3 product ready to go and still share price is at all time low.

logic says to buy here but with this share and management, logic just doesn't work

catch you later
Posted at 04/4/2023 07:10 by sicilian_kan
Yet more good news published on NTCD-M3. So Destiny has world leading, best in class data in P2. The P3 is fully funded by a partner, in a deal worth up to $570m in milestones with tiered, double-digit royalties. Destiny retains a majority of all non-US rights, so further M3 deals are possible. There is £7m in cash.

And this is:

(a) despite M3 having been brought in as a backup to derisk Destiny's pipeline, with the main drug also due to partner for P3 this year in an even bigger market and with an up front likely; and

(b) with Destiny having only acquired M3 around 3 years before for just £2m. To turn that in such a short period of time into a deal worth $570m in milestones and tiered double digit royalties with majority non-US rights retained is remarkable and demonstrates with external validation the judgment of the board, the commerciality of Destiny's pipeline and their deal making ability. I note too the background of Neil Clark, who was involved in both CeNeS and Ergomed, the former was sold and the latter has become a very successful company.

Meanwhilst, some posters on here ignore the above and choose to focus on:

1. Suggesting an 80% collapse in share price on open on the day an excellent RNS comes out validating M3 with a further antibiotic now added to US guidelines.

2. Criticising a poster for not being here enough.

3. Blaming others for having not invested at the bottom, despite everything suggesting (see above) that Destiny is heading in the right direction and that given time things will turn.
Posted at 06/3/2023 15:58 by smithie6
what do ppl think

1) is the big fall from 55p to 35p a red flag, to avoid the shares ?

2) the share price has fallen due to collaboration deal combined with a fair % of dilution due to cash raise.
The share price is at ~ a medium term low.

3) the stage 3 trial for the collaboration for the drug to resist/treat CDificile does not start until 2024

4) the advance payment for the collaboration was only 1 million. imo a small amount & hence a dilutive cash raise needed to be created

5) the % royalty of the development partner for sales outside north America is not revealed.
it reduces the % for DEST.

6) the share price has struggled to stay as high as the placing price for new shares....inferring that shareholders are not enthused.


Can someone put a glossy spin on the above 'cause where I am looking from I struggle to be enthused by these points.
Posted at 27/2/2023 08:13 by sev22
Here is the introduction to FinnCap's broker note this morning:

NTCD-M3 US partnering deal and fundraise: value inflection.

Destiny Pharma has announced a US partnering deal for the Phase III development and commercialisation of NTCD-M3 for the prevention of the recurrence of Clostridioides difficile infection. Destiny Pharma gains upfront and milestone payments of up to US$570m and royalties on sales of 10-18% on a tiered basis. The deal is predicated on Destiny strengthening its balance sheet and it plans to raise £7m via a Placing and up to £1m in an Open Offer. The deal de-risks the R&D pipeline and the Destiny Pharma equity story, especially with the prospect of partnering deals on NTCD-M3 (ex-US) and XF-73. We introduce 2023E and 2024E forecasts and reduce our riskadjusted DCF target price from 306p to 285p, given the higher share count.

- NTCD-M3 US Partnering deal. Destiny Pharma has announced a partnering deal for the Phase III development, registration and marketing of NTCD-M3 in the US with Sebela Pharmaceuticals, a GI-focused pharma PE-backed company with a strong track record of growing revenues and profitability. Destiny will gain US$20m in upfront and near-term milestone payments, up to US$550m in sales-based milestone payments and 10-18% royalties on end-market sales. Sebela will incur all Phase III, registration and marketing costs. The Group had announced close to the end of 2022 that it expected to sign a partnering deal in early 2023 and so has delivered it.

- Associated fundraise. The US deal with Sebela is dependent on Destiny strengthening its balance sheet and as such, Destiny plans to launch a Placing and Open Offer to raise up to £8m. The additional capital will allow Destiny to progress other programmes such as XF-73 more quickly. Destiny has re-iterated it plans to sign a partnering deal for the Phase III development and commercialisation of XF-73 in 2023, which could be another value inflection point.

- De-risking R&D pipeline and equity story. While our forecasts included an assumption of a partnering deal for NTCD-M3 (although on slightly different terms), that Destiny has concluded such a deal, validates the NTCD-M3 development programme, removes the need for Destiny to fund expensive Phase II trials, de-risks the R&D pipeline and de-risks the overall equity story for Destiny Pharma. As such, with the prospect of further partnering deal possible in 2023 and in 2024, the shares have several further potential catalysts.

- Valuation and forecasts. We introduce 2023E and 2024E forecasts; there are minimal changes to our 2022E forecasts. Destiny has noted that the signing of the Sebela deal and associated fundraise would provide a cash runway until late-2024. As we expect further partnering deals on XF-73 (potentially in 2023) and NTCD-M3 ex-US in 2024, we make the assumption that the Group will be funded beyond its guidance and include placeholder revenue in 2024 to that effect. Including the upfront payment from Sebela, the likely milestone payments and tiered royalties and assuming a £7m equity raise but with an increased share count, our risk-adjusted DCF target price reduces from 306p to 285p.
Destiny Pharma share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |